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The prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infections varies in the literature, a
problem complicated by the lack of routine screening procedures; however, limited data suggest that hVISA has been associated
with persistent bloodstream infections (BSI) and vancomycin failure, yet these studies have been confounded by design issues.
We conducted this study to compare the characteristics of patients with BSI caused by hVISA with those with vancomycin-sus-
ceptible Staphylococcus aureus (VSSA) treated with vancomycin. This retrospective, multicenter matched (1:1) cohort study
compared the clinical characteristics and outcomes of hVISA and VSSA. Patients with hVISAmethicillin-resistant Staphylococ-
cus aureus (MRSA) BSI from 2004 to 2012 were matched to VSSA-MRSA BSI patients. The primary outcome was failure of van-
comycin treatment, defined as a composite of persistent bacteremia (>7 days), persistent signs and symptoms, change of MRSA
antibiotic, recurrent BSI, or MRSA-related mortality. We identified 122 matched cases. The overall vancomycin failure rate was
57% (82% hVISA versus 33%VSSA; P< 0.001). The individual components of failure in hVISA versus VSSA were persistent bac-
teremia, 59% versus 21% (P< 0.001); change inMRSA therapy, 54% versus 25% (P 0.001); MRSA-related mortality, 21% ver-
sus 10% (P 0.081); and recurrence of BSI, 26% versus 2% (P< 0.001). Using logistic regression analysis and adjusting for co-
variates, hVISA (adjusted odds ratio [aOR], 11.1; 95% confidence interval [CI], 4.3 to 28.7) and intensive care unit (ICU)
admission (aOR, 4.5; 95% CI, 1.8 to 11.6) were still independently associated with vancomycin failure. Relative to VSSA BSI, pa-
tients with hVISA were more likely to experience failure of vancomycin treatment, including persistent bacteremia and recur-
rence. Our results indicate that hVISA was responsible for considerable morbidity.
Methicillin-resistant Staphylococcus aureus (MRSA) infectionscontinue to pose a dilemma in the hospital environment as
well as in the community setting (1, 2). Vancomycin has been the
primary treatment for infections caused by MRSA; however, re-
duced susceptibility to vancomycin has emerged in vancomycin-
intermediate S. aureus (VISA) and vancomycin-resistant S. aureus
(VRSA) as well as heterogeneous vancomycin-intermediate S. au-
reus (hVISA), compromising the utility of this antibiotic (3–5). In
previous studies, the prevalence of the hVISA phenotype has
ranged from 0 to 29.2% of MRSA isolates. Several factors may
influence the wide variance in prevalence, including geographical
area, site of infection, and screening/detection methods (macro-
Etest versus population analysis profile) (6–11). In contrast to
VISA or VRSA strains, hVISA strains are often undetected since
these organisms are considered vancomycin susceptible on the
basis of traditional MIC testing performed by clinical microbiol-
ogy laboratories (12–14). The gold standard for detecting hVISA is
the modified population analysis profile (mPAP), referencing the
area under the curve (AUC) of the test strain to hVISA control
strain Mu3 (15). Due to the labor-intensive nature of the PAP
method and the lack of standardization by the Clinical and Labo-
ratory Standards Institute (CLSI), it is not routinely performed as
a screening/detection method for hVISA. The inability to detect
subpopulations with reduced vancomycin susceptibility in rou-
tine practice makes accurate estimation of the prevalence and clin-
ical impact of hVISA difficult to establish.
Understanding and managing patients with hVISA is a major
therapeutic challenge, because it has been shown that patients
with hVISA infections are likely to fail therapy with vancomycin
(14, 16, 17). A recent systematic review and meta-analysis evalu-
ated the significance of hVISA and reported a 2.37-fold-increased
risk of glycopeptide failure (95% confidence interval [CI], 1.53 to
3.67) compared to vancomycin-susceptible S. aureus (VSSA) (8).
This is even more concerning considering that hVISA has been
linked to high bacterial load infections, prolonged fever and bac-
teremia, and increased hospital length of stay (10, 18, 19). Other
clinical characteristics that have been correlated with hVISA are
elevated vancomycin MICs (e.g., 1 mg/liter) and prior vanco-
mycin use (6, 17, 19, 20).
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Prior studies have associated hVISA with poorer outcomes;
however, these studies differed in detection methods and outcome
analysis, making it difficult to determine the true significance of
hVISA. Further, the severity of illness and frequency of high-risk
infection sources among hVISA patients complicated the ability to
directly compare their outcomes to those of patients with VSSA
infections. Therefore, we investigated the morbidity and mortality
of a multicenter cohort of patients with bloodstream infection
(BSI) caused by hVISA and compared the results to those of
patients with VSSA treated with vancomycin by matching pa-
tients according to infection source. A secondary aim was to
correlate success or failure on the basis of organism character-
istics such as vancomycin susceptibility including heteroresis-
tance, MIC, genetic polymorphism (agr and staphylococcal
cassette mec [SCCmec] type), delta-hemolysin activity, and
vancomycin trough concentrations in serum.
(An abstract containing results from this study was presented
in platform format at the 52nd Interscience Conference on Anti-
microbial Agents and Chemotherapy [ICAAC] in San Francisco,
CA, on 10 September 2012.)
MATERIALS AND METHODS
Study design and population. This was a retrospective, multicenter (the
Detroit Medical Center, the Ohio State University Medical Center, the
Albany Medical Center, the University of Pittsburgh Medical Center, and
the Veterans Affairs Medical Center in Providence, RI), matched (1:1)
cohort study comparing the outcomes of hVISA infections versus VSSA
infections in patients with MRSA BSI treated with vancomycin from Jan-
uary 2004 to August 2012. The institutional review board at each of the
participating medical centers approved the study. MRSA BSI patients
were defined as patients with MRSA in blood cultures that met the Centers
for Disease Control and Prevention (CDC) criteria for primary blood-
stream infection (21). Adult patients aged18 years identified from clin-
ical blood cultures positive for MRSA with susceptible vancomycin MIC
(2 mg/liter) and who received vancomycin for 72 h were eligible for
inclusion in this study. Patients with hVISA were matched 1:1 to VSSA
patients based on age group (50 years, 50 to 70 years, and 70 years),
site of infection (including concomitant site of MRSA infection), and year
of infection 2 years.
Microbiological and molecular data. For patients with multiple
MRSA blood cultures, the first MRSA isolate for each patient was obtained
for extensive microbiology evaluation at the Anti-Infective Research Lab-
oratory (Detroit, MI). Vancomycin MIC was determined by broth mi-
crodilution performed in agreement with CLSI guidelines using the cur-
rent susceptible breakpoint of 2 mg/liter and the Etest method
according to the manufacturer’s instructions (bioMérieux, Durham, NC)
(22).
A random selection of 1,249 MRSA bloodstream isolates from all in-
volved institutions were initially screened using the Macro Etest method
described by Wootton and colleagues (15, 23) and confirmed by vanco-
mycin mPAP. Vancomycin mPAP was determined on all strains at an
inoculum of approximately 1  108 CFU/ml. Fifty microliters of this
suspension was plated on vancomycin containing BHI at increasing con-
centrations (0, 0.5, 1, 1.5, 2, 3, 4, and 8 mg/liter) using an automated spiral
dispenser (Whitley Automated Spiral Plater, Bon Whitley Scientific, West
Yorkshire, United Kingdom). After incubation at 35°C for 48 h, colony
counts (log10 CFU/ml) were determined using a laser colony counter
(ProtoCOL; Synbiosis, Cambridge, United Kingdom). The AUC was de-
termined for each test isolate and compared to the AUC of the reference
strain, Mu3 (ATCC 700698). The test isolate was considered an hVISA or
VSSA if the population analysis profile area under the curve (PAP-AUC)
ratio of the test isolate to Mu3 was 0.9 or 0.9, respectively, as previ-
ously described by Wootton and colleagues (6, 15).
The staphylococcal cassette mec (SCCmec) type and the agr group for
the isolates were characterized using multiplex PCR, as described else-
where (24, 25). The expression of the agr gene cluster was determined by
quantitating delta-hemolysin production utilizing a previously described
method by cross-streaking test strains perpendicular to RN4220 as previ-
ously described (26).
Data collection.Patient data collection included baseline demograph-
ics such as age, sex, comorbidities, hospitalization history within 180 days
before admission, receipt of prior antibiotic therapy (48 h in the previ-
ous 30 days), use of concomitant antibiotics, concurrent sites of MRSA
infection, acute physiology and chronic health evaluation II (APACHE II)
score, and Charlson comorbidity index at the first positive blood culture.
Additional data collected were duration of bacteremia, pharmacokinetic
variables (dosing and vancomycin concentrations in serum), length of
hospital stay, and infection outcomes including duration of signs and
symptoms and 30-day mortality. Calculation of vancomycin AUC/MIC
was estimated from the daily dose given during the first 24 h of therapy
divided by clearance derived from previous literature (27). The concom-
itant site with MRSA infection was determined by assessment of other
MRSA-positive cultures at the time of onset of MRSA and/or clinical
description by the treating physician in the medical record.
Outcome assessment. For the purposes of data analysis, patients were
stratified into 2 groups according to the presence of hVISA (hVISA versus
non-hVISA [VSSA]). Thirty-day MRSA-related mortality, time to clear-
ance of MRSA from the bloodstream, resolution of signs and symptoms of
infection, and length of hospital stay after the first positive blood culture
were assessed. The length of hospital stay was defined as the number of
days after the onset of infection. Failure of vancomycin treatment was
defined by the following criteria: (i) nonresolving bacteremia for at least 7
days while on vancomycin (17, 20, 28); (ii) new onset or worsening of
signs or symptoms of infection while on vancomycin therapy (7, 28); (iii)
either change of MRSA intravenous antibiotic or addition to vancomycin
of a second antimicrobial agent targeted against MRSA, necessitated by
lack of resolution (2, 29, 30); and (iv) recurrent BSI defined as a positive
blood culture for MRSA within 60 days of completion of antimicrobial
therapy (30). Death was considered to be attributed to MRSA infection as
described previously (28, 31) if one of the following criteria was present:
(i) blood cultures were positive for MRSA at the time of death, (ii) death
occurred before resolution of signs and symptoms of MRSA infection,
(iii) death occurred 14 days after the onset of MRSA without another
explanation, (iv) autopsy findings indicated MRSA as a cause of death,
and (v) MRSA was indicated as a cause of death on the death certificate.
Length of hospital stay after the onset of infection was defined as the time
from the first MRSA-positive culture until discharge or death (31).
Statistical analysis. Categorical variables were compared by Mc-
Nemar’s test, continuous variables were compared by paired Student’s t
test, and ordinal variables were compared by the Wilcoxon signed rank
test. Appropriateness of age matching was examined by paired Student’s
t test. Multivariable analyses were performed to determine the indepen-
dent association of vancomycin treatment failure while adjusting for con-
founding variables. All variables significantly associated with the outcome
on univariate analysis (P 0.2) were included in the explanatory multi-
variable model using a backward stepwise approach. All tests were two-
tailed, and P values of0.05 were considered to be statistically significant.
SPSS Statistics, IBM SPSS software, version 20.0 (SPSS Inc., Chicago, IL),
was used for all calculations.
RESULTS
We identified and included 61 matched pairs during the study
period that met the criteria, for a total of 122 BSI. All 122 patients
received vancomycin for initial treatment for MRSA BSI for at
least 72 h, and the median duration of vancomycin treatment was
9 days (interquartile range [IQR], 5 to 14). The primary sources of
infection for these cases were as follows: infective endocarditis, 48
patients (39.3%); pneumonia, 10 patients (8.2%); intravenous
(IV) catheter-related infection, 30 patients (24.6%); bone and
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joint infections, 18 patients (14.8%); skin and soft tissue infection,
12 patients (9.8%); and unknown source, 4 patients (3.3%). Over-
all, 40 (32.8%) patients received source control, and there was no
difference between hVISA and VSSA groups in source control:
32.8% versus 32.8%, respectively (P  0.99). Within the specific
primary source of infection, no statistical difference was found
between hVISA and VSSA. There were no differences in baseline
demographics and clinical characteristics of patients with hVISA
and VSSA except for two characteristics (Table 1). Presence of
hVISA was significantly associated with decubitus ulcers (P 
0.044) and a vancomycin MIC of1 mg/liter by the Etest method
(P 0.038) compared to VSSA. However, there was no statistical
difference between patients with hVISA and VSSA with respect to
age, severity of illness (APACHE II), Charlson comorbidity index,
or history of vancomycin use, hospitalization, and MRSA infec-
tion. Vancomycin concentrations in serum did not differ between
the two groups, with median initial vancomycin trough concen-
trations in serum of 12.1 mg/liter (IQR, 6.8 to 18.3 mg/liter) and
11.7 mg/liter (IQR, 8.4 to 16 mg/liter) for the hVISA and VSSA
groups, respectively (P 0.790). The vancomycin MIC distribu-
tion determined by broth microdilution and Etest susceptibility
methods and the hVISA frequency are presented in Fig. 1 and
2, respectively.
Overall vancomycin treatment failure was 57.3% (70/122), and
patients with hVISA were associated with a significantly higher
vancomycin treatment failure (82%) than patients with VSSA
(32.8%; P 0.001) (Fig. 3). Of interest, each criterion for vanco-
mycin treatment failure was more common with hVISA: persis-
tent bacteremia (59% versus 21.3%, P  0.001), change or addi-
tion of anti-MRSA antibiotic (54.1% versus 24.6%, P  0.001),
and recurrence of MRSA BSI after 60 days from end of treatment
(25.5% versus 1.9%, P 0.001). Signs and symptoms were more
prolonged, by an average of 1 day, in the hVISA group than in the
VSSA group with a median of 3 days (IQR, 1 to 10) versus 2 days
(IQR, 1 to 3), respectively (P  0.031). Median duration of bac-
teremia was 3 days longer in the hVISA group than in the VSSA
group: 7 days (IQR, 3 to 11.5) versus 4 days (IQR, 2 to 7), respec-
tively (P  0.003). Thirty-day MRSA infection-related mortality
TABLE 1 Baseline demographic and clinical features of MRSA associated with hVISA compared to VSSAa
Feature hVISA (n 61) VSSA (n 61) P value
Baseline demographics
Age (mean yr SD) 57.5 14.3 56.5 16.7 0.745
Weight (kg) 72.6 (63–87.3) 75 (67.9–85) 0.278
Creatinine clearance (ml/min) 41.1 (18–82.1) 55 (29.6–95.3) 0.134
APACHE II score 12 (8–18) 10 (7–15) 0.251
Charlson index 3 (1–4) 2 (1–4) 0.404
Female sex 30 (49.2) 21 (34.4) 0.099
ICU admission 29 (47.5) 23 (37.7) 0.272
Previous hospitalization 32 (52.5) 34 (55.7) 0.716
Previous surgery 4 (6.6) 10 (16.4) 0.088
Previous antibiotics 30 (49.2) 24 (39.3) 0.274
Previous VAN 13 (21.3) 11 (18) 0.649
Prior MRSA infection 9 (14.8) 8 (13.1) 0.794
Renal disease 28 (45.9) 26 (42.6) 0.715
Chronic kidney disease 6 (9.8) 8 (13.1) 0.570
Hemodialysis 17 (27.9) 10 (16.4) 0.127
Diabetes 20 (32.8) 16 (26.2) 0.427
Decubitus ulcer 11 (18) 3 (4.9) 0.044
Injection drug user 17 (27.9) 19 (31.1) 0.691
Prosthetic device/hardware 4 (6.6) 4 (6.6) 1.00
Clinical characteristics
VAN BMD MIC, 2 mg/liter 18 (29.5) 7 (11.7) 0.015
VAN Etest MIC,1 mg/liter 43 (71.7) 32 (53.3) 0.038
VAN duration (days) 8 (5–15) 9 (5–15) 0.640
VAN initial trough (n 109) 12.1 (6.8–18.3) (n 56) 11.7 (8.4–16) (n 53) 0.790
Initial VAN trough,15 mg/liter 20 (35.7) 14 (26.4) 0.295
AUC/MIC 445.4 (282.3–855) 467 (344–728.4) 0.605
AUC/MIC,400 34 (55.7) 39 (63.9) 0.356
SCCmec type II 28 (46.7) 20 (33.3) 0.136
agr group II 29 (48.3) 28 (46.7) 0.855
agr dysfunctional activity 11 (19.3) 11 (19.3) 1.000
Clinical outcomes
Duration of bacteremia (days) 7 (3–11) 4 (2–7) 0.003
Duration of signs/symptoms (days) 3 (1–10) 2 (1–3) 0.031
Length of stay (days) 24 (14–44.5) 16 (9.5–30.5) 0.022
Length of stay after first positive blood culture (days) 22 (12–39) 13 (9–28) 0.021
a Values are followed by percentage in parentheses for categorical data, unless otherwise specified; median values are followed by the interquartile range in parentheses. BMD, broth
microdilution; VAN, vancomycin; AUC, area under the concentration-time curve over 24 h.
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was doubled in the group with hVISA infection, yet its incidence
was not statistically significant compared to VSSA-related mortal-
ity (21.3% versus 9.8%, respectively; P  0.081). Likewise, no
difference in all-cause 30-day mortality was detected between
hVISA and VSSA patients (24.6% versus 11.5%, respectively; P
0.076). Compared to VSSA, hVISA was associated with longer
total hospital length of stay (median difference of 8 days, P 
0.022) as well as longer length of stay after the onset of infection
(average difference of 9 days, P  0.021). Overall, a total of 47
cases (38.5%) were treated with an alternative agent to vancomy-
cin or with combination therapy. Of these, 33 cases (70.2%)
switched to daptomycin as an alternative agent; 23 (48.9%) of
these were in the hVISA group versus 10 (21.3%) in the VSSA
group. The remaining alternative agents used were intravenous
trimethoprim-sulfamethoxazole (4 cases, 8.5%), intravenous lin-
ezolid (5 cases, 10.6%), and gentamicin in combination with van-
comycin (5 cases, 10.6%).
Characteristics associated with vancomycin treatment failure
in univariate and multivariable analyses are shown in Tables 2 and
3. No relationship with vancomycin treatment failure was identi-
fied, with initial vancomycin trough concentrations in serum of
15 mg/liter compared to 15 mg/liter, 60% versus 55.9%, re-
spectively (P 0.686). Additionally, there was no relationship of
vancomycin treatment failure, with an AUC24/MIC (ratio of area
under the concentration curve over 24 h divided by the MIC) of
400 compared to400, 59.2% versus 56.2%, respectively, (P
0.741). There was a higher frequency of hVISA and ICU admission
among the patients with vancomycin treatment failure than of
successful treatment in the univariate analyses. These covariates
along with APACHE II score, SCCmec type II, renal disease, and
high-risk infection source (31) (infective endocarditis, pneumo-
nia, or bone and joint infection) were evaluated in the logistic
regression model, and three covariates remained in the model.
Heterogeneous vancomycin-intermediate Staphylococcus aureus
(adjusted odds ratio [aOR], 11.1; 95% CI, 4.3 to 28.7) and inten-
sive care unit admission (aOR, 4.5; 95% CI, 1.8 to 11.6) were
independently associated with vancomycin treatment failure.
DISCUSSION
Our study implies that the odds of vancomycin treatment failure
were 11 times greater for a patient with hVISA BSI than for a
patient with VSSA BSI. Similar to what was reported in previous
literature, vancomycin treatment failure was common in MRSA
bacteremia and was more pronounced in patients infected with
hVISA. Prior studies reported comparable failure proportions
with a range from 68.4% to 100% of hVISA infections (10, 17,
32–34), using similar definitions of vancomycin treatment failure.
The most frequently observed component of failure was persistent
bacteremia, which was a commonly used criterion in other studies
(16–18, 20, 33). Change of vancomycin to an alternative therapy
(e.g., daptomycin) or addition of another anti-MRSA antibiotic
(e.g., gentamicin) was also a common contributor to the vanco-
mycin failure rate. This criterion of the composite for vancomycin
treatment failure has been included in a previous study (29) but
has not always been considered in the MRSA bacteremia litera-
ture. All of our 33 patients with hVISA and 13/15 patients with
VSSA that changed in MRSA therapy were also deemed to have
experienced failure of vancomycin treatment by persistent bacte-
remia. The remaining 2 VSSA cases that had a change in MRSA
therapy occurred before 2008, indicating that the change may be
due to an overall poor clinical response to vancomycin and not
necessarily to an elevated high vancomycin MIC as noted in the
recommendations of the 2011 MRSA clinical practice guidelines
by the Infectious Diseases Society of America (2). Another impor-
tant outcome in patients with hVISA for vancomycin treatment
failure was recurrence of MRSA BSI 60 days from the end of ther-
apy. The percentage of 60-day recurrence that we observed was
similar to that reported by Lodise and colleagues (13%) in a sin-
gle-center cohort of MRSA bacteremia (30). However, this is the
first study that evaluated recurrence and found an association
with hVISA infection.
Despite the association with prolonged bacteremia, prolonged
symptoms, and recurrence, this study did not observe a difference
in 30-day MRSA-related mortality associated with hVISA. The
overall 30-day MRSA infection-related mortality in this group of
MRSA BSI was 15.6%, which is lower than rates reported by other
studies, which range from 17.3% to 28.4% (7, 17, 20). While pa-
tients with hVISA infection had a higher mortality rate than pa-
tients with VSSA, this did not reach statistical significance. Since
hVISA is associated with factors known to influence mortality
such as high vancomycin MIC, persistent bacteremia, and recur-
rence of BSI, one might expect an increased mortality compared to
that of VSSA BSI. One explanation for the lack of a mortality
difference in our study is that the sample size was chosen to detect
FIG 2 Vancomycin MIC distribution by the Etest method and hVISA fre-
quency for all MRSA isolates.
FIG 1 Vancomycin MIC distribution by the broth microdilution method and
hVISA frequency for all MRSA isolates.
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a difference in vancomycin failure and not specifically infection-
related mortality. However, the observed phenomenon may also
be related to hVISA strain characteristics that contribute to per-
sistence, rather than virulence. It has been suggested that hVISA
and VISA strains have reduced virulence factors, leading to a de-
creased host immune response, resulting in reduced mortality but
an increase in persistent infections (35, 36). van Hal and col-
leagues recently reported that the presence of hVISA is an inde-
pendent predictor of survival, specifically in ST239 MRSA strains
(19). In contrast, our current findings did not find hVISA to be
correlated with survival. No molecular typing (e.g., spa typing or
pulsed-field gel electrophoresis) was completed for this study, as
the clonal relatedness of isolates is unlikely to have a direct influ-
ence on response to therapy; however, identification of specific
MRSA clones would be advantageous for epidemiological pur-
poses.
High vancomycin MIC has also been associated with hVISA in
the literature (6, 19, 20) and is consistent with our findings indi-
cating that the frequency of hVISA increases with vancomycin
MIC by both broth microdilution and Etest methods. Our Etest
method displayed statistical significance with patients with hVISA
when MICs were greater than 1 mg/liter, analogous to the results
of Musta and colleagues (20). Prior literature in MRSA bacteremia
suggests that high vancomycin MIC is associated with treatment
failure (37). However, our data indicated that a vancomycin Etest
MIC of 1 mg/liter had higher treatment failure but the differ-
ence was not statistically significant (66.7% versus 56.9%; P 
0.273) compared to treatment success; therefore, these data may
imply that hVISA BSI irrespective of vancomycin MIC may fail on
vancomycin treatment. Patients with hVISA had similar propor-
tions of having adequate vancomycin trough concentrations and
an AUC24/MIC of400. However, these patients still had a higher
proportion of treatment failure. Rose and colleagues have previ-
ously demonstrated using in vitro pharmacokinetics and pharma-
codynamics models that even high-dose vancomycin exposure (5
g IV every 12 h; AUC24/MIC for the free, unbounded fraction of
vancomycin [ƒAUC24/MIC], 799) did not result in a significant
impact on hVISA strains (38).
We controlled for potential confounding variables by match-
ing in this retrospective multicenter cohort study; however, this
study does have some limitations. First, all of these MRSA isolates
were obtained from the first positive culture for screening and
identification of hVISA by mPAP, which could overlook hVISA
arising in subsequent cultures. Second, although the macro Etest
method for screening for hVISA has been found to have a high
specificity (39), it is possible that some hVISA strains may be mis-
classified as negative; however, all strains were confirmed by
mPAP for matching purposes if the macro Etest initially identified
the strain as VSSA or hVISA. It was not possible to complete the
removal of the source of infection in all patients, and this con-
founding factor may affect our primary outcome since it was not
controlled by our matching design. The small sample size pre-
cludes extensive analysis of confounding factors; nonetheless, this
multicenter study is the first matched-cohort comparative study
of hVISA confirmed by the gold standard of mPAP, representing a
significant advancement in the available evidence (15). Finally,
selection bias is a potential concern with clinical outcomes in ret-
rospective studies when vancomycin susceptibility has been iden-
tified; however, clinicians were unaware of hVISA presence, thus
not altering therapy or management during hospitalization.
In conclusion, the results propose that patients with MRSA
BSI caused by hVISA are at increased risk of vancomycin treat-
ment failure. Irrespective of high vancomycin MIC, hVISA is
independently associated with vancomycin treatment failure.
One of the major issues for identifying patients infected with
this organism is the lack of a reliable and minimized-labor
commercial product for routine screening. Current methods
are expensive, lack sufficient sensitivity, are labor-intensive,
FIG 3 Comparison of hVISA and VSSA for composite vancomycin treatment failure. VAN, vancomycin; MRSA, methicillin-resistant Staphylococcus aureus;
BSI, bloodstream infection; *, change of MRSA intravenous antibiotic or addition to vancomycin of a second antimicrobial agent targeted against MRSA; °,
30-day mortality MRSA infection related.
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and are not standardized. It is still considered difficult to have
a prospective study without proper and rapid identification of
hVISA. This may be only the tip of the iceberg, as larger sur-
veillance studies are needed to evaluate the true prevalence of
hVISA. Our data would support that hVISA identification is
important based on the overall impact on patient outcomes
including the association of prolonged days of bacteremia, lon-
ger days of persistent signs and symptoms, extended length of
hospitalization, higher frequencies of MRSA BSI recurrence,
and an 11-times-greater risk of vancomycin treatment failure.
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TABLE 2 Univariate analysis of clinical features of MRSA associated with vancomycin treatment failurea
Feature Success (n 52) Failure (n 70) P value
Patient characteristics
Age (mean yr SD) 56.7 17.9 57.2 13.5 0.868
Weight (kg) 75.3 (67.2–86.4) 72.6 (63–86.8) 0.303
Creatinine clearance (ml/min) 52.8 (28.1–93.9) 49 (19.8–89) 0.669
APACHE II score 10 (6–14.8) 11.5 (8–18) 0.174
Charlson index 2 (0.5–3) 3 (1–5) 0.090
Female sex 22 (42.3) 29 (41.4) 0.922
ICU admission 13 (25) 39 (55.7) 0.001
Previous hospitalization 27 (51.9) 39 (55.7) 0.678
Previous surgery 8 (15.4) 6 (8.6) 0.243
Previous antibiotics 22 (42.3) 32 (45.7) 0.708
Previous VAN 9 (17.3) 15 (21.4) 0.571
Prior MRSA infection 8 (15.4) 9 (12.9) 0.690
Renal disease 19 (36.5) 35 (50) 0.120
Chronic kidney disease 8 (15.4) 6 (8.6) 0.243
Hemodialysis 10 (19.2) 17 (24.3) 0.506
Diabetes 14 (26.9) 22 (31.4) 0.589
Decubitus ulcer 4 (7.7) 10 (14.3) 0.390
Injection drug user 15 (28.8) 21 (30) 0.890
Prosthetic device/hardware 2 (3.8) 6 (8.6) 0.464
Infective endocarditis 18 (34.6) 30 (42.9) 0.357
Pneumonia 3 (5.8) 7 (10) 0.400
Bone or joint infection 7 (13.5) 11 (15.7) 0.729
High-risk infection groupb 28 (53.8) 48 (68.6) 0.097
MRSA isolate characteristics
hVISA 11 (21.2) 50 (71.4) 0.001
VAN BMD MIC, 2 mg/liter 9 (17.6) 16 (22.9) 0.485
VAN Etest MIC,1 mg/liter 29 (56.9) 46 (66.7) 0.273
SCCmec type II 16 (31.4) 32 (46.4) 0.097
agr group II 24 (47.1) 33 (47.8) 0.934
agr dysfunctional activity 7 (14.9) 15 (22.7) 0.300
Clinical characteristics
VAN duration (days) 9.5 (6–14) 8 (4–15) 0.226
VAN initial trough (n 109) 11.7 (8.3–18) (n 45) 11.7 (7.8–16.6) (n 64) 0.638
Initial VAN trough, 15 mg/liter 15 (34.1) 19 (29.7) 0.628
AUC/MIC 446.9 (334.9–717.6) 466.1 (289.3–853.5) 0.979
AUC/MIC,400 32 (61.5) 41 (58.6) 0.741
Length of stay (days) 15.5 (9–29.8) 24 (13–45) 0.003
Length of stay after first positive blood culture (days) 11 (8–26.3) 22 (13–42) 0.001
a Values are followed by percentage in parentheses for categorical data, unless otherwise specified; median values are followed by the interquartile range in parentheses. BMD, broth
microdilution; VAN, vancomycin; AUC, area under the concentration-time curve over 24 h.
b Infection caused by infective endocarditis, pneumonia, or bone and joint infection.




(95% CI) P value
hVISA 11.138 (4.316–28.742) 0.001
Admission to ICU 4.507 (1.751–11.597) 0.002
High-risk infectiona 2.528 (1.000–6.391) 0.050
a Infection caused by infective endocarditis, pneumonia, or bone and joint infection.
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